header logo image


Page 822«..1020..821822823824..830840..»

The GOP’s willful blindness to Trump’s abuses is putting our democracy in peril – The Boston Globe

November 22nd, 2019 5:54 pm

Over the past ten days, a dozen current and former government officials have testified before the House impeachment inquiry. There is only one conclusion to be drawn from their hours of testimony: the president of the United States has repeatedly committed flagrantly impeachable offenses.

Donald Trump used the power of the presidency to extort a foreign government. He conditioned a White House visit for Ukraines new president and then later nearly $400 million dollars in military assistance on a public announcement of an investigation of former vice president Joe Biden, a key political rival.

As Gordon Sondland, US Ambassador to the European Union, testified on Wednesday, this was common knowledge within the Trump administration. Everyone, said Sondland, was in the loop.

Every witness offered clear and unambiguous evidence of this quid pro quo. To deny it happened is, quite simply, to deny reality.

And yet congressional Republicans appear intent on doing just that.

For all their sound and fury, GOP members offered the American people nothing that looked even remotely like a compelling defense of Trumps actions during the House impeachment inquiry. When they werent floating fantastical and evidence-free conspiracy theories about the Bidens, misplaced servers, and Ukrainian intervention in the 2016 election, they were spitting out one non sequitur argument after another.

They harped on the fact that Kyiv never actually investigated Biden willfully ignoring the presidents all-out campaign to win just such an investigation. Trump pulled numerous administration figures and his personal lawyer Rudy Giuliani into the shakedown campaign, and pressured the Ukrainian president, Volodymyr Zelensky, himself.

They said the president was worried about corruption in Ukraine disregarding the fact that he never once mentioned corruption in his calls with Zelensky and never once sought information from his own national security officials about Ukraines anti-corruption efforts.

They seized on the fact that none of the witnesses ever heard the president use the words bribery or extortion or specifically say he was conditioning military aid on a Biden investigation as if criminals regularly articulate their crimes and their precise motivations for committing them.

They said Ukraine eventually got their military assistance while remaining completely incurious about the fact that Trump delayed that aid for three months and only released it after the whistleblower complaint emerged. No Republican seriously questioned the fact that Trump made an investigation of Biden a condition for a White House visit by Zelensky which in of itself is a clear abuse of presidential power.

They misrepresented testimony and smeared witnesses. They railed against the whistleblower for offering second-hand evidence, oblivious to the individuals seated 20 feet in front of them who offered first-hand testimony. They hectored those who offered inconvenient evidence of the presidents guilt. They focused their questioning on individual trees while ignoring the vast and lush forest of presidential misconduct.

After nearly three years of Republicans defending Trumps corruption, his shredding of democratic norms, and his abuses of presidential power, none of us should be surprised.

But make no mistake, this latest cover-up is the nadir of Americas anti-democratic descent. Its not just that Trump sought to use his office for personal gain. Its that he tried to enlist a foreign government in influencing an American election just as he did with Russia in 2016.

When high crimes and misdemeanors as severe and profound as these can be summarily dismissed by members of the presidents own party; when the president can be shielded from accountability and, in effect, operate above the law; when he can openly seek to subvert elections without consequence, but rather with cheerleading, thats not democracy. Its authoritarian rule.

To some, this might sound like alarmism or hysteria. Its not.

The GOPs acquiescence to Trumps crimes should be a hair-on-fire moment for the American people a direct assault on the idea of the rule of law and a government of the people, by the people, and for the people.

What is even more terrifying is that Trump is probably a 50/50 bet to be re-elected. And if he wins, it would quite likely come once again with a victory in the Electoral College but a defeat in the popular vote.

If youve got a president twice-elected with a minority of votes, operating with virtual impunity, and using his office to pressure foreign governments to tarnish his political rivals, its not a sign of a healthy democracy. Rather, its a clear indication that Americas 243-year experiment in democratic governance is teetering on the brink. If Americans arent terrified of where all this is heading, they damn well should be.

Michael A. Cohens column appears regularly in the Globe. Follow him on Twitter @speechboy71.

Read the original here:
The GOP's willful blindness to Trump's abuses is putting our democracy in peril - The Boston Globe

Read More...

Texans’ DeAndre Hopkins gives two touchdown balls to his blind mom in heartwarming game tradition – CBS Sports

November 22nd, 2019 5:54 pm

DeAndre Hopkins helped the Houston Texans take control of the AFC South with a 20-17 win over the Indianapolis Colts on Thursday. He found the end zone twice and each time celebrated by giving the ball to a fan in the crowd. But it wasn't just any fan -- it was Hopkins' mother, Sabrina Greenlee, who is blind.

She always sits in the same seats at NRG Stadium during Texans home games. After hauling in the touchdown catch, Hopkins went right over to his mother and handed her the football. It's what he does whenever he scores during Texans homes games.

Greenlee has been blind since 2002, according to CBS KHOU. She was attacked by another woman who believed that Greenlee was sleeping with her boyfriend. Acid -- specifically a mix of bleach and lye -- was involved in the assault, which ultimately caused the blindness, and Greenlee was left in a coma for over two weeks. Although she attends nearly every Texans home game, she has never been able to see Hopkins, who was a rookie in 2013, play in the NFL.

Hopkins put on quite the performance for his mother with one of his best outings of the 2019 season. The Texans star wideout caught six passes for 94 yards and a pair of touchdowns, including a 30-yard strike from Deshaun Watson that ended up being the game-winning score. It was Hopkins' first multi-touchdown game since Houston's Week 1 contest against the New Orleans Saints.

Hopkins' huge performance gave the Texans the division lead and he was able to share one of his key touchdowns with his mother.

See the original post:
Texans' DeAndre Hopkins gives two touchdown balls to his blind mom in heartwarming game tradition - CBS Sports

Read More...

Will Republicans continue to engage in willful blindness? | TheHill – The Hill

November 22nd, 2019 5:54 pm

One of us is a liberal Democrat who voted for Hillary ClintonHillary Diane Rodham ClintonDemocratic strategist laments 'low bar' for Biden debate performance Wasserman Schultz makes bid for House Appropriations Committee gavel Trump to hold campaign rally in Pennsylvania next month MORE and learned about decoding Donald TrumpDonald John TrumpWatergate prosecutor says that Sondland testimony was 'tipping point' for Trump In private moment with Trump, Justice Kennedy pushed for Kavanaugh Supreme Court nomination: book Obama: 'Everybody needs to chill out' about differences between 2020 candidates MOREs words from his former attorney, Michael CohenMichael Dean CohenWill Republicans continue to engage in willful blindness? 3 reasons why impeachment fatigue has already set in Day 2 impeachment ratings drop by more than 1 million from first day MORE. The other is a conservative Republican who voted for Mr. Trump, served briefly as his White House communications director and thus also has experience trying to translate Trumps elliptical code words.

During the impeachment hearings so far, two Republican members of the House Intelligence Committee Reps. Jim JordanJames (Jim) Daniel JordanDiplomat seen rolling his eyes amid testy impeachment exchange with Jordan Live coverage: Impeachment spotlight shifts to Fiona Hill, David Holmes House GOP wants Senate Republicans to do more on impeachment MORE of Ohio and Elise StefanikElise Marie StefanikLive coverage: Impeachment spotlight shifts to Fiona Hill, David Holmes The Hill's Morning Report - Sondland stuns; Dems pull punches in fifth debate How House Republicans have stayed unified on impeachment MORE of New York were particularly ready to buy into these Trump code-word games.

Cohen, who served as Mr. Trumps attorney for 10 years, was quite experienced with Trumps reliance on code words, often hearing him use message words that were exactly the opposite of the truth.For example, in 2018, Cohen was asked by the Senate and House intelligence committees whether he had had discussions with Russians during the 2016 presidential campaign about the Trump Organization building a Trump Tower in Moscow. As Cohen subsequently testified, the answer was yes, and Trump was fully briefed. After receiving this question from the two committees, Cohen visited with Trump in the Oval Office to get guidance as to how he should answer. The code words were clear: Michael, no Russia, no discussions, no Russia, Trump told him. Cohen got the party-line message to lie, consistent with Trump's public denials during the campaign. (Cohen subsequently pled guilty and is serving prison time, in part as a result of following Trump's instructions-by-code to lie to Congress, knowing he was doing so for Trump's benefit.)

During last weeks televised impeachment hearings, committee Republicans accepted the truth of Trumps denials: No quid pro quo, no quid pro quo, no quid pro quo. They said there was no direct evidence of Trump linking military aid to Ukraine with requiring Ukraine's President Zelensky to announce corruption investigations of Democrats.

But what exactly did Trump say during his call with Zelensky? Wouldnt that be direct evidence?Lets re-read key parts of the summary transcript of the call.

First, the context: President Zelensky said his country was "almost ready to buy more Javelins" anti-tank missiles from the United States for defense purposes.

Trump then said,immediatelyafter Zelensky's reference to military weapons: "I would like you to do a favor though."

The word "though," in plain English, is the same as "but" or "however."

Then Trump immediately referenced the need to investigate the Democrats, based on the utterly debunked ultra-right conspiracy theory that Ukraine had the Democratic National Committee (DNC) server that had been hacked into by the Russians during the 2016 campaign. Trump mentioned the company, Crowdstrike, which helped the DNC to track the email hack to the Russians.

Then comes his direct ask:I would like you to find out what happened with this whole situation with Ukraine, they say Crowdstrike ... The server, they say Ukraine has it.

Note the words "I would like you to." This is more than just asking a "favor." It is consistent with Lt. Col. Vidman's interpretation at Tuesday's hearings that it sounds more like an "order" than asking for a "favor."

Just two paragraphs later in the summary transcript not more than a couple of minutes of conversation Trump mentions asecond favor to Zelensky. Specifically, Trump calls this the other thing.

Theres a lot of talk about Bidens son, that Biden stopped the prosecution and a lot of people want to find out about that so if you can look into it ... , he said.

Republicans try to deny the second favor but they are undone by the words the other thing. In the context of Zelensky asking for a shipment of Javelin missiles, Trump asks for two favors benefitting him personally and politically.

Trump has trouble pronouncing the three Latin words, quid pro quo. Here are three other Latin words that Republicans should recall when reading the summary transcript of the Trump-Zelensky July 25 call:"Res ipsa loquitur" "the thing speaks for itself."

Even indirect or so-called circumstantial evidence is still evidence that can lead to a conviction, based on a jurys reasonable inferences. We are compelled to ask Republicans: If you heard the Godfather telling his consiglieri, I dont like that guy, and shortly thereafter "that guy is shot, would you vote to acquit because there was no direct evidence of the Godfather giving the order?

We shall see whether Republicans will continue their willful blindness to the evidence, direct and circumstantial, until they will have to vote whether to impeach in the House and remove in the Senate. If they do, we shall see, about a year from now at the polls, whether Republicans engaging in such sophistry will be held accountable and sent back to private life.

Lanny Davis, an attorney in Washington, served as President Clintons special counsel from 1996 to 1998 and was a member of President George W. Bush's Privacy and Civil Liberties Oversight Board, 2006-07. He is a co-founder of the law firm of Davis Goldberg & Gaiper PLLC and the strategic media and public affairs firm Trident DMG. He authored "Crisis Tales: Five Rules for Coping with Crises in Business, Politics and Life" (2013). Follow him on Twitter @LannyDavis.

Anthony ScaramucciAnthony ScaramucciWill Republicans continue to engage in willful blindness? Scaramucci: Trump sees Bloomberg as threat Scaramucci: Trump will be gone by March 2020 MOREis an American entrepreneur, founder and co-managing partner of SkyBridge Capital. He served briefly as White House communications director. Follow him on Twitter@Scaramucci.

See original here:
Will Republicans continue to engage in willful blindness? | TheHill - The Hill

Read More...

Genetic condition that leads to blindness discovered in monkeys for the first time – AOP

November 22nd, 2019 5:54 pm

Scientists hope that the discovery of a sight-threatening genetic syndrome in monkeys could offer new avenues for developing treatments for the condition.

Writing in Experimental Eye Research, researchers highlight that three rhesus macaques monkeys were found to have Bardet-Biedl Syndrome (BBS), which leads to vision loss, kidney dysfunction and other symptoms.

BBS is part of a larger family of diseases that affect the retina called retinitis pigmentosa.

The syndrome occurs in one in 140,000 to 160,000 North American births.

Dr Martha Neuringer, from Oregon Health & Science University, highlighted that there is no cure for BBS at present.

Having a naturally occurring animal model for the condition could help us find one in the future, she shared.

Scientists also hope that having an animal model of BBS may lead to a greater understanding of a variety of retinitis pigmentosa diseases.

Image credit: Pixabay/christels

Read the original here:
Genetic condition that leads to blindness discovered in monkeys for the first time - AOP

Read More...

Padma Shri Award Winner Dr. R.V. Ramani Speaks about the Role of Technology in Eliminating Curable Blindness – indica News

November 22nd, 2019 5:54 pm

Ritu Jha-

Dr. R.V. Ramani, managing trustee of Sankara Eye Foundation (SEF), one of the leading eye care service providers in India on being honored with the Padma Shri award [A Civilian Award bestowed by Govt.of.India]early this year says that these are moral boosters not only for the individuals but also for the organizations to which he or she belongs to.

It encourages you to do more and also encourages your confidence. There are people who appreciate the good things in life. So that is something that makes you feel positive about it.

Dr.Ramani was felicitated at the SEF USA annual banquet on Nov. 9 at Paradise Ballrooms in Fremont, California. Philanthropists, business and social leaders, and donors from the Indian-American community came together to celebrate the accomplishment of 1.96 million free eye surgeries through Sankara hospitals and over 80,000 free eye surgeries with their partner, as well as pledge support to fulfill the mission of eradicating curable blindness in India.

Dr. Ramani told indica with a smile on the sidelines of the conference, where people surrounded him congratulating him and taking a look at the prestigious Padma Shri medal he wore on his suit, You feel you were able to disseminate some good

It was a pleasant surprise; I wasnt aware of it, he said, on learning about the award.

The Sankara Eye Hospital was first established in 1977 to eliminate curable eye blindness in India, during his speech Dr. Ramani shared not just about his vision but about the upcoming hospitals in India as well as the use of technology, specifically artificial intelligence (AI) to ensure early diagnosis and prevention.

There are nine established super specialty SEF hospitals and three new SEF hospitals being built in Indore, Hyderabad, and Mumbai. Bihar Sankara Eye Hospital has partnered with Akhand Jyoti Hospital, based in Masti Chak, Bihar to help the underserved. The Sankara Eye Hospital in Indore is being inaugurated January 2020.

Dr. Ramani noted that Bihar has been slow with its establishment of SEF hospitals. He said the awareness is there but you need to create a sound foundation, that is why it took this much time. He believes to run an organization, one needs like-minded people. So together they aim and reach out to more people and be of service and disseminate role models so that more and more people will get on board.

On the usage of technology he said, Every day we see thousands of patients so data mining is going to help us a lot in the long term. Whatever we see and learn we try to integrate into future services.

It helps in both prevention and diagnosis. Preventative eye care for children and curative eye care for adults.

The annual banquet also held a panel conducted by Sridharan Krishnamurthy, president and board member of SEF USA where SEF India and its board members, share about why they joined Sankara and their work.

Bharath Balasubmaium, President Sankara Eye Hospital in Coimbatore, India told indica on how they are using Artificial Intelligence(AI) to take leverage of data generated through 10 hospitals said, weve started bringing technology 15 years back where weve revamped our client serve mechanism to data-based capturing mechanism. So, hospitals have been integrated and each hospital is connected and all the functional hospital generate data in real-time. And we monitor the progress of each location.

Balasubmaium, who has been associated for the past two decades with Sankara said in 2009, they ensured all hospitals should be integrated and data was visible and started researching AI to predict disease.

When asked how using AI, how its helping, he said to try to understand the reasons for the diseases and try to understand there are any patterns that have come out of the information that is available in the hospital data.

With the AI technology, which we have been developing for the past four years and have been trying to understand and come out the trends in diabetic retinopathy. We have patients with diabetes and so we are understanding the patterns and trends, Balasubmaium said.

Explaining further he said that with cataracts and now with diabetes increasing, diabetic retinopathy is becoming prevalent.

Lots of patients have a cataract, which is the leading cause of blindness, he said.

Balasubmaium also added that its not just the patients coming to the hospitals which generates data but also the people on the ground surveying in the field using the Sankara Electronic Remote Vision Information System (SERVIS) an app.

We are in the process of collecting the information and coming out with heat maps which have the job imaging in eye disease. Again, all this is real-time data collection

Balasubmaium says, with AI we are looking at what more can be done in preventing eye diseases.

The intention is to eliminate curable blindness, said Balasubmaium.

Visit link:
Padma Shri Award Winner Dr. R.V. Ramani Speaks about the Role of Technology in Eliminating Curable Blindness - indica News

Read More...

Biogen Announces Enrollment Completion of Global Phase 3 Gene Therapy Study for an Inherited Retinal Disorder – Yahoo Finance

November 22nd, 2019 5:54 pm

Timrepigene emparvovec is a potential first-in-class AAV2 gene therapy for the treatment of choroideremia, a rare, degenerative, X-linked retinal disorder that leads to blindness

CAMBRIDGE, Mass., Nov. 21, 2019 (GLOBE NEWSWIRE) -- Biogen Inc.(BIIB) announced today the enrollment of the last patient in the global Phase 3 STAR clinical study, which is evaluating the investigational gene therapy timrepigene emparvovec (BIIB111/AAV2-REP1) for the treatment of choroideremia (CHM). CHM is a rare, degenerative, X-linked inherited retinal disorder that leads to blindness.

We are excited to advance innovative investigational treatments for inherited retinal disorders that have significant unmet medical need due to the lack of treatment options, said Alfred Sandrock, Jr., M.D., Ph.D., Executive Vice President, Research and Development, and Chief Medical Officer at Biogen. Timrepigene emparvovec could be a transformative gene therapy for individuals living with choroideremia who would otherwise face inevitable blindness. Completing enrollment of our Phase 3 study represents a significant milestone in bringing this new potential therapy to patients.

STAR is a randomized, masked, prospective, parallel-controlled group Phase 3 study that enrolled 170 adult males with CHM. The study is evaluating the safety and efficacy of a single subretinal injection of timrepigene emparvovec. The primary endpoint is the proportion of patients with an improvement of at least 15 letters from baseline in best corrected visual acuity (BCVA) at 12 months post treatment as measured by the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity protocol. The STAR study was initiated based on proof-of-concept data from Phase 1/2 studies, which indicated that at month 24, over 90 percent of patients treated with timrepigene emparvovec via targeted subretinal injection maintained visual acuity instead of experiencing the natural decline in BCVA expected in this degenerative disease. In a subset of treated patients with moderate to severe visual acuity loss, 21 percent experienced a gain in visual acuity of at least 15 ETDRS letters from baseline as compared to one percent of untreated patients in a natural history study.

CHM primarily affects males and is caused by a loss of function in the CHM gene which encodes the Rab escort protein-1 (REP-1). The REP-1 protein plays a role in intracellular protein trafficking, and the loss of function in the CHM gene leads to abnormal intracellular protein trafficking and impaired elimination of waste products from the retinal pigment epithelium and photoreceptors. Initially, patients with CHM experience poor night vision and over time, progressive visual loss ultimately leads to blindness.

Biogen added timrepigene emparvovec to its portfolio in June 2019 as part of its acquisition of Nightstar Therapeutics.

For more information about the Phase 3 STAR study, visit http://www.clinicaltrials.gov (NCT03496012).

About timrepigene emparvovec (BIIB111/AAV2-REP1)Timrepigene emparvovec is an AAV2 vector administered by subretinal injection, which aims to provide a functioning CHM gene and expression of the REP-1 protein to restore membrane trafficking and thereby slow, stop or potentially reverse decline in vision. Data from the Phase 1/2 studies demonstrated a slower rate of decline in visual acuity in patients treated with timrepigene emparvovec compared to untreated patients in the natural history study. In addition, some patients treated with timrepigene emparvovec showed improvements in visual acuity. The studies also demonstrated that timrepigene emparvovec was generally well tolerated with an acceptable safety profile.

Timrepigene emparvovec has received regenerative medicine advanced therapy (RMAT) designation from the U.S. Food and Drug Administration (FDA), which includes all of the benefits of the fast track and breakthrough therapy designation programs and orphan drug designations in the U.S., Europe and Japan. The safety and efficacy of a single subretinal injection of timrepigene emparvovec is currently being evaluated in the ongoing Phase 3 STAR study.

About Biogen At Biogen, our mission is clear: we are pioneers in neuroscience. Biogen discovers, develops, and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. One of the worlds first global biotechnology companies, Biogen was founded in 1978 by Charles Weissmann, Heinz Schaller, Kenneth Murray, and Nobel Prize winners Walter Gilbert and Phillip Sharp. Today Biogen has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first approved treatment for spinal muscular atrophy, commercializes biosimilars of advanced biologics, and is focused on advancing research programs in multiple sclerosis and neuroimmunology, neuromuscular disorders, movement disorders, Alzheimers disease and dementia, ophthalmology, immunology, neurocognitive disorders, acute neurology, and pain.

Story continues

We routinely post information that may be important to investors on our website atwww.biogen.com. To learn more, please visitwww.biogen.comand follow us on social media Twitter,LinkedIn,Facebook,YouTube.

Biogen Safe Harbor StatementThis news release contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, relating to the potential, benefits, safety and efficacy of timrepigene emparvovec; the potential clinical effects of timrepigene emparvovec; results from the Phase 1/2 studies of timrepigene emparvovec; the clinical development program for timrepigene emparvovec; the treatment of CHM; the potential of our commercial business and pipeline programs, including timrepigene emparvovec; and risks and uncertainties associated with drug development and commercialization. These forward-looking statements may be accompanied by words such as aim, anticipate, believe, could, estimate, expect, forecast, intend, may, plan, potential, possible, will, would and other words and terms of similar meaning. Drug development and commercialization involve a high degree of risk and only a small number of research and development programs result in commercialization of a product. Results in early stage clinical trials may not be indicative of full results or results from later stage or larger scale clinical trials and do not ensure regulatory approval. You should not place undue reliance on these statements, or the scientific data presented.

These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements, including without limitation, uncertainty of success in the development and potential commercialization of timrepigene emparvovec; unexpected concerns may arise from additional data, analysis or results obtained during the STAR study; regulatory authorities may require additional information or further studies, or may fail or refuse to approve or may delay approval of our drug candidates, including timrepigene emparvovec; the occurrence of adverse safety events; the risks of other unexpected hurdles, costs or delays; failure to protect and enforce our data, intellectual property and other proprietary rights and uncertainties relating to intellectual property claims and challenges; and product liability claims. The foregoing sets forth many, but not all, of the factors that could cause actual results to differ from our expectations in any forward-looking statement. Investors should consider this cautionary statement, as well as the risk factors identified in our most recent annual or quarterly report and in other reports we have filed with the U.S. Securities and Exchange Commission. These statements are based on our current beliefs and expectations and speak only as of the date of this news release. We do not undertake any obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.

View original post here:
Biogen Announces Enrollment Completion of Global Phase 3 Gene Therapy Study for an Inherited Retinal Disorder - Yahoo Finance

Read More...

How Conservatives Turned the Color-Blind Constitution Against Racial Progress – The Atlantic

November 22nd, 2019 5:54 pm

This massive societal shift was met with backlash from some white citizens, who resented attempts at leveling the playing field through policies such as busing, racial quotas, affirmative action, and disparate-impact standards. They argued that these disruptive measures infringed on their personal liberties and had the effect of discriminating against them.

As desegregationist policies reached states and cities, white parents vacated public-school systems rather than integrate them, and the Supreme Court began hearing cases from white claimants who cited the unfairness of remedial policies governing hiring and promotion practices, university admissions, and government-contract allocations.

But the dynamics soon shifted. It wasnt long before those groups that were once making color-conscious arguments in support of racial segregation began using the principles of color-blind constitutionalism to assert that racially progressive policies were discriminating against white Americans.

Meanwhile, Thurgood Marshall ascended to the Court and grew dismayed that color blindness was now the main thrust of the legal argument against practical measures seeking to establish a racially egalitarian society. He wrote in his Regents of the University of California v. Bakke dissent, It is more than a little ironic that, after several hundred years of class-based discrimination against Negroes, the Court is unwilling to hold that a class-based remedy for that discrimination is permissible.

Adam Serwer: The Supreme Court is headed back to the 19th century

In Marshalls formulation, color-blind constitutionalism was a wholly appropriate approach for obtaining the equal rights of a subjugated people, but an insufficient guide to unmaking the societal disadvantages that racism had wrought. That is, he considered it in the words of the old gospel hymnIt once was blind, but now it sees.

This view accords with what scholars have long known. The political theorist Iris Marion Young argued that when unequal societies throw off statutory constraints and declare all citizens equals henceforth, preexisting group hierarchies are perpetuated unless proactively addressed. The upshot is that color-blind constitutionalism in unequal societies compels the lifting of state-sanctioned discrimination, but the ensuing remediation must be color-conscious in the same way that the harms were.

More recent conservative-leaning Supreme Courts seem to disagree. In a series of cases that tackle racial preferences and attempts at racial redress, the Court has found that a color-blind reading of the Constitution complicates or outright rejects color-conscious policies, even if they are implemented with the intent of furthering racial equality. For example, in Adarand Constructors, Inc. v. Pea (1995), a case challenging affirmative action in government contracts, the Court established that race-based classifications must meet strict scrutiny, the highest standard of judicial review. In Shelby County v. Holder (2013), the Court ruled that a measure intended to protect voters of color in jurisdictions with a history of racial discrimination was unconstitutional, effectively gutting the Voting Rights Act of 1965. The Court determined that Michigans affirmative-action ban was constitutional in Schuette v. Coalition to Defend Affirmative Action (2014).

View post:
How Conservatives Turned the Color-Blind Constitution Against Racial Progress - The Atlantic

Read More...

Philadelphia Police Investigating Brutal Beating of McDonald’s Worker Who Refused to Give Free Food to Teens – Newsweek

November 22nd, 2019 5:54 pm

A group of teenage boys allegedly knocked a Philadelphia McDonald's worker unconscious after she wouldn't give them free food.

Charm Sullivan, 17, was working behind the counter at the McDonald's restaurant on Broad Street and Hunting Park on Wednesday night when the incident unfolded, her cousin Khadijah Lovett told NBC Philadelphia.

A group of boys asked her to give them free food. When Sullivan said no, at least four boys started to attack her, according to Lovett. The teenager tried to flee from the assailants by going to the bathroom at the store. But the boys followed her and continued their attack.

Lovett said the teens carried on beating the girl outside in the parking lot, where she was found unconscious between two cars. She claimed they "assaulted her several times," and hit her with a brick in front of the restaurant.

A photo of Sullivan seen by NBC shows her face with a severely swollen right eye, and red marks on her skin.

Sullivan went to hospital and returned home, before being sent back after she started to feel dizzy and threw up.

Lovett told NBC Philadelphia her cousin is "hurt" and will never return to work again.

"The only thing she keeps saying is she doesn't know. Why her. Why her?" she said. Lovett said of the culprits: "You're rude and you're ignorant and you're disrespectful and you wouldn't want nothing like this to happen to your mom, your sister."

The manager at the branch of McDonald's where Sullivan works refused to speak to NBC. McDonald's did not immediately respond to a request for comment from Newsweek.

Police have launched an investigation and are looking for the culprits.

Earlier this year in a separate attack in Australia, a McDonald's worker was blasted in the face with a fire extinguisher at a drive-thru, in an incident which could have left her "blinded."

In June, three males and one female drove up to the kiosk in a dark sedan at a Melbourne restaurant, staffed by Kimberley Friend, who was 21 at the time. The group taunted Friend, then drove away. Around 10 minutes later, they came back and a fire extinghuisher was let off in her face while others in the car filmed.

Friend told Australia's 9News at the time: "It [happened] so fast. I inhaled and tasted it straight away. [I thought], 'this is poison.'"

Her partner took her to a nearby hospital, where nurses told her the attack "could have caused blindness so, very lucky... it's not a joke, it was malicious," Friend said.

See the original post:
Philadelphia Police Investigating Brutal Beating of McDonald's Worker Who Refused to Give Free Food to Teens - Newsweek

Read More...

An Estimated 184,000 Children, Under the Age of 15, Sent to the Emergency Room for Toy-related Injuries in One Year, According to the CPSC – PR Web

November 22nd, 2019 5:54 pm

Prevent Blindness has declared December as Safe Toys and Gifts Awareness Month.

CHICAGO (PRWEB) November 21, 2019

Last year, the U.S. Consumer Product Safety Commission (CPSC) issued a report stating there were an estimated 251,700 toy-related injuries treated in U.S. hospital emergency departments. Forty-four percent of the estimated injuries were to the head and face area, the most commonly affected area of the body.

According to the CPSC, of the 251,700 estimated toy-related, emergency department-treated injuries, an estimated:

Prevent Blindness, the nations oldest non-profit eye health organization, has declared December as Safe Toys and Gifts Awareness month, to help shoppers select the best gifts for children.

For those considering purchasing sports equipment, Prevent Blindness suggests that the proper sports eye protection also be included. Recommendations may be found at http://www.preventblindness.org/recommended-sports-eye-protectors.

Sunglasses with UV protection can be a helpful gift for adults and children. Only buy sunglasses that provide a clear statement about how much UV radiation is blocked. The label should clearly state the sunglasses block 99 to 100 percent of UV-A and UV-B rays.

For all other gift ideas, Prevent Blindness recommends:

By taking a few cautionary steps to give gifts that are meaningful, safe and age-appropriate for children, you can help make sure that the holidays are festive and bright, said Jeff Todd, president and CEO of Prevent Blindness.

For more information on safe toys and gifts for children, please visit http://www.preventblindness.org/safe-toy-checklist or call Prevent Blindness at (800) 331-2020.

About Prevent Blindness Founded in 1908, Prevent Blindness is the nation's leading volunteer eye health and safety organization dedicated to fighting blindness and saving sight. Focused on promoting a continuum of vision care, Prevent Blindness touches the lives of millions of people each year through public and professional education, advocacy, certified vision screening and training, community and patient service programs and research. These services are made possible through the generous support of the American public. Together with a network of affiliates, Prevent Blindness is committed to eliminating preventable blindness in America. For more information, or to make a contribution to the sight-saving fund, call 1-800-331-2020. Or, visit us on the Web at preventblindness.org or facebook.com/preventblindness.

Share article on social media or email:

Original post:
An Estimated 184,000 Children, Under the Age of 15, Sent to the Emergency Room for Toy-related Injuries in One Year, According to the CPSC - PR Web

Read More...

Scientists unravel mysteries of cells’ whiplike extensions | The Source – Washington University in St. Louis Newsroom

November 22nd, 2019 5:54 pm

Cilia, or flagella whiplike appendages on cells perform diverse tasks required to keep the body healthy. When cilia malfunction, the consequences can be devastating, causing a range of problems, from blindness, to lung and kidney diseases, to congenital heart defects. Now, scientists have revealed the firstdetailed lookat the inner structure of cilia.

The newly revealed structure offers a starting point to begin exploring how cilia are assembled during development, how they are maintained over a cells life span, and how they might become dysfunctional if some of the cogs in these complex molecular machines are mutated or missing. The structure of these microscopic molecular machines common to cells in organisms from algae to people potentially will answer questions about human health and disease.

The research, by investigators at Washington University School of Medicine in St. Louis and Harvard Medical School, was published recently in the journal Cell.

This new study is exciting because it fills in a lot of missing information about the structure of cilia, said senior authorRui Zhang, assistant professor of biochemistry and molecular biophysics at Washington University. When cilia dont work properly, bad things happen. We need to know details of the structure in order to develop treatments for diseases, or strategies to prevent the developmental defects that can occur in the early embryo if the cilia are not functioning as they should.

In the respiratory tract, cilia move mucus and protect against viral and bacterial illnesses. In the reproductive tract, they propel sperm to fertilize an egg. Cilia also perform vital tasks in the brain, the kidney, the pancreas and in bone growth. And in the earliest stages of development, the rotational motion of specialized cilia in the embryo defines the bodys left-right asymmetry and where organs are placed. Without properly functioning cilia, the heart may not end up on the left side, where it should be, and it may not function properly.

Cilia are implicated in multiple human disorders, including polycystic kidney disease, which affects some 600,000 Americans and requires dialysis; primary ciliary dyskinesia, which causes chronic lung disease, misplaced organs and infertility; Bardet-Biedl syndrome, which causes patients to become blind in childhood and leads to diabetes, kidney disease and extreme obesity; and many congenital heart defects, which occur when left-right asymmetry goes awry and require complex surgeries to repair.

In the new study, the researchers used a technique called single particle cryo-electron microscopy to get a first look at 33 specific proteins arranged inside cilia within structures called ciliary microtubule doublets in a strict repeating pattern.

Before this work, everyone assumed these proteins inside cilia just stabilize the structure, which is true for a subset of the proteins, especially when you consider the forces produced by the continuous beating of the cilia, Zhang said. But based on how they are arranged inside this structure, we believe these proteins are doing many more things.

Since many of the proteins protrude through the cilia, Zhang and his colleagues speculate that they may allow for communication between the inside and the outside of the ciliary microtubule doublets; govern the function of enzymes that make important biochemical reactions possible; and sense changes in the calcium concentration of the environment, which plays a role in triggering the cilia to beat.

Among the proteins identified, five are associated with diseases that have been studied in mice and people, said co-authorSusan K. Dutcher, professor of genetics at Washington University. But until now, no one knew that these proteins were found inside cilia. We are just beginning to understand their roles in normal and disease states.

The researchers studied cilia in a type of algae calledChlamydomonas reinhardtii, which are single-celled organisms that have cilia structurally and biochemically similar to those of more complex organisms, including people. One question Dutcher is interested in answering is how the proteins making up cilia structure govern the type of motion that the cilia perform. The cilia of single-celledC. reinhardtiiare capable of more than one type of motion.

In some situations, the cilia are doing what you might consider a breast stroke, Dutcher said. In others, the motion is more of an S-shaped wave. The cilia of many cells in mammals can only produce one of these motions. But the single-celledC. reinhardtii, perhaps to help it adapt to its environment, can switch between them. Thats why were studying algae at a medical school the genetic problems we can study in the cilia of these organisms are similar to the ones that can occur in people, often with devastating consequences.

Zhang, Dutcher and their colleagues have plans to use the latest techniques of cryo-electron microscopy to study theChlamydomonas mutants of each of the 33 proteins inside cilia to seek answers to many questions that have arisen from this new and detailed knowledge of the structure.

Originally published by the School of Medicine

Original post:
Scientists unravel mysteries of cells' whiplike extensions | The Source - Washington University in St. Louis Newsroom

Read More...

Glaucoma Surgery Devices Market is Expected to Register Lucrative Growth 2026 – Downey Magazine

November 22nd, 2019 5:54 pm

Glaucoma is an ocular disease which affects the optic nerve of the iris and progression of the same results in vision loss and blindness. According to the World Health Organization (WHO), glaucoma is the most cause of blindness across the world.

Currently, there are no existing treatments for glaucoma; however, some commercially available therapies focus on reducing the intraocular pressure, which is responsible for the development and progression of the disease. The treatment for glaucoma starts with topical eye drops, which is an alternative used to delay surgery.

Photodynamic therapy and laser therapy are effective solutions that perform well with surgery options. Rise in the number of glaucoma cases, easy availability of medical insurance coverage for diagnosis and treatment, and growth in demand for minimally invasive glaucoma surgeries are expected to drive the global glaucoma surgery devices market during the forecast period. Furthermore, increase in health care expenditure and rise in geriatric population are expected to fuel the glaucoma surgery devices market during the forecasted period.

Request a Brochure of Glaucoma Surgery Devices Market Report

https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=40916

The global glaucoma surgery devices market can be segmented into types of product, types of surgery, end-user, and region. Based on product type, the market is segregated into punches, USC planer, USC marker, USC shaver, Alger brushes and probes, forceps, glaucoma drainage devices, knives, and others. In terms of types of surgery, the glaucoma surgery devices market can be divided into minimally invasive glaucoma surgeries (MIGS), tube shunt implantation, trabeculectomy, cyclophotocoagulation, and others.

Among these segments, the MIGS segment is anticipated to dominate the market during the forecasted period owing to rising demand for minimally invasive and patient-friendly procedures. Based on end-user, the glaucoma surgery devices market can be categorized into diagnostic centers, eye-hospitals, and others.

The global glaucoma surgery devices market has a presence of several regional players which have a huge market share in emerging countries operating at regional or country level. In terms of geography, the global glaucoma surgery devices market can be divided into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The U.S. dominates the market due to the increase in acceptance of treatment options.

Additionally, rising awareness among patients regarding glaucoma and the introduction of favorable reimbursement policies are anticipated to fuel the glaucoma surgery devices market in North America during the forecast period. Europe is the second largest market for the glaucoma surgery devices market.

Request for a Discount on Glaucoma Surgery Devices Market Report

https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=40916

The market in Asia Pacific, especially in countries such as India, China, and Japan, is anticipated to expand at a rapid pace in the next few years due to rising awareness regarding glaucoma surgeries and booming medical tourism in this region. The market in Middle East and Africa and Latin America is projected to expand at a sluggish pace in the near future.

Major players operating in the global glaucoma surgery devices market are Abbott Laboratories, Glaukos Corporation, Alcon, Inc., ASICO, Carl Zeiss Meditec AG, Katalyst Surgical, Nidek Co., Ltd., Lumenis Ltd., Ziemer Ophthalmic Systems AG, and Iridex Corporation.

Continue reading here:
Glaucoma Surgery Devices Market is Expected to Register Lucrative Growth 2026 - Downey Magazine

Read More...

Ophthalmic Knives Market is Expected To Increase Up to US$ 460 mn by 2027 – Downey Magazine

November 22nd, 2019 5:54 pm

Ophthalmic knives, also known as microsurgical knives, are specifically designed for uncomplicated and hassle-free eye surgeries. Ophthalmic knives are available in different shapes and angles for accurate incisions in the cornea and sclera during an eye surgery. These knives consist of blades that are strong and break-resistant, and made of different materials such as stainless steel, diamond, sapphire, and silicon to provide sharpness and an accurate opening.

Growth of the globalophthalmic knives marketis attributed to increase in the global geriatric population, which is more prone to cataracts and refractive eye errors. Moreover, increase in the incidences of glaucoma, vitreoretinal, diabetes retinopathy, corneal transplantation, and technological advancements are boosting the growth of the global ophthalmic knives market.

North America dominated the global ophthalmic knives market in 2018, and this trend is anticipated to continue during the forecast period. This is attributed to rise in the prevalence of ophthalmic diseases, awareness about minimal invasive surgeries, and surge in vision impairment in the region.

However, increase in the number of local manufacturers is creating a pricing pressure, which is likely to hamper the growth of the global ophthalmic knives market in North America in the latter half of the forecast period. Asia Pacific is expected to be a highly lucrative market for ophthalmic knives during the forecast period.

Request a Sample of Ophthalmic Knives Market Report

https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=66695

High Prevalence of Eye Disorders and Rise in Awareness to Drive Usage of Ophthalmic Knives

The incidences of eye diseases has increased across the globe, and is expected to rise significantly in the near future. Ophthalmic disorders that need surgery are cataract, glaucoma, age-related muscular disorders, corneal transplantation, and others. Globally, eye disorders such as cataract, glaucoma, andage-related macular degeneration(AMD) are the leading causes of blindness and visual impairment. The high prevalence of eye disorders is fueling the demand for minimal invasive surgeries with ophthalmic knives.

Cataract is the most prevalent eye disorder across the globe. Hence, the demand for eye surgeries to treat this disorder is high. Rise in cataract surgeries has induced manufacturers to focus on developing efficient and versatile ophthalmic knives. According to the NCBI journal, the rate of blindness caused by cataract is rising at 1 million per year, globally, and the number of people undergoing cataract operations is increasing by 4 million to 5 million per year.

According to a WHO report (2010), glaucoma was estimated to cause blindness in 4.5 million people, which is around 12% of all global blindness, while AMD was the third-leading cause of blindness after cataract and glaucoma, with a global prevalence of 8.7%.

The incidences of eye disorders such as cataract are expected to rise, due to the increase in the geriatric population. According to research, the prevalence of cataract is three times higher in India compared to that in the U.S., with 82% people in India aged between 75 years and 83 years affected by cataract as compared to only 46% in the U.S. in the same age group.

Increase in Geriatric Population Increases the Need of Surgeries

The geriatric population is likely to suffer from cataract more often than the younger population. Moreover, the geriatric population is increasing at a faster pace than the younger population.

Increase in the geriatric population aged above 65 years is projected to surge the incidences of eye disorders, which, in turn, is anticipated to boost the need for corrective surgeries and treatment of these disorders. Eye surgeries require ophthalmic knives for successful incisions. These factors are likely to boost the global ophthalmic knives market.

According to the United Nations, the geriatric population aged above 60 is expected to double by 2050 and triple by 2100, an increase from 962 million in 2017 to 2.1 billion in 2050, and 3.1 billion by 2100.

Adoption of Technologically-Advanced Blades

Technological advancement is key for the growth of the medical devices market. Hence, manufacturers are keen on developing and offering innovative solutions to surgeons and patients.Bio blade is an innovative ophthalmic surgical blade recommended for uncomplicated eye surgeries, with excellent sharpness and consistency for smooth and uniform incisions.

Request for a Discount on Ophthalmic Knives Market Report

https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=66695

Bio blades are manufactured from highly purified stainless steel, which makes the blade hard and break-resistant, and are highly preferred by surgeons. Rise in the adoption of bio blades offers considerable opportunities to the providers of advanced ophthalmic care across the world.

Key Players Driving Global Ophthalmic Knives Market

The global ophthalmic knives market is fragmented in terms of number of players. Key players in the global ophthalmic knives market include Sidapharm, Surgical Specialties Corporation, Pfm medical ag, Alcon, Surgi Edge, Eagle Lab, Mani, Inc., Optitech Eyecare, Unique Technologies Inc., and Shah Eye Care Pvt. Ltd.

Original post:
Ophthalmic Knives Market is Expected To Increase Up to US$ 460 mn by 2027 - Downey Magazine

Read More...

Vision Care Market Poised to Expand at a Robust Pace Over 2028 – Statsflash

November 22nd, 2019 5:54 pm

Global Vision Care Market: Overview

An upcoming report on the global vision care market by TMR Research could be a valuable source of information for major stakeholders in the market. The report would offer a brilliant study of the market with its focus on market dynamics, segmentation, and geographical outreach. It could prove to be a useful guideline for players wanting to cement their position in the global vision care market.

Vision care or maintaining eye health are the major concerns globally. Vision-related diseases elevate the risk of blindness or significant vision loss. Good vision eases out daily important activities such as writing, reading, and watching. These also helps in communication, health, work, developmental learning and impacts in overall quality of life. Various factors such as chronic diseases, pollution, and unhealthy diets can affect in functioning of the eyes. Thus, plenty of products and treatments are developed to control vision related problems.

Request Brochure of Vision Care Market Report for more Industry Insights @CLICK HERE NOW

Global Vision Care Market: Trends and Opportunities

Increasing usage of laptops, tablets, PCs, and phones in day-to-day lives, growing older population, and rising number of vision-related problems are believed to be driving the global vision care market. Apart from blindness, there are various vision related problems such as astigmatism, myopia, macular edema, retinal tears, and diabetic retinopathy. Growing demand from the population aged 65+ years, increasing healthcare industry, and rapid technological advancement in eye care products are expected to boost the global vision care market.

Although, declining eye care treatment rate, product design, and brand name are also projected to hinder the growth in the global vision care market. However, growing brand awareness and paradigm shift in the consumer behavior are projected to propel the global vision care market.

Global Vision Care Market: Market Potential

Growing advent of innovative product launches is expected to fuel the global vision care market. There are several products available for vision care such as contact lens, glass lens, contact lens solution, and IOLs. The incorporation of technology in developing vision care products increase efficiency, improves quality and precision of the final product, and reduces overall cost. Increasing demand for restoring normal vision with eyeglasses or contact lenses, cost-effectiveness in using vision care products instead of LASIK eye surgery, and rising advanced medical treatment are believed to be driving the global vision care market.

Global Vision Care Market: Regional Outlook

Region wise, there is a possibility of North America to lead the global vision care market as the region has witnessed rapid development in healthcare industry. Growing population suffering from eye related disorders, rapid technological advancement, and increasing healthcare industry with advanced infrastructure could also be fueling the global vision care market. The prominent countries in this region are US and Canada. Easy availability of glass lens and innovative product launches with the help of modern technology are projected to propel the global vision care market in these countries.

Get TOC of Vision Care Market Report for more Industry Insights @CLICK HERE NOW

Global Vision Care Market: Competitive Dynamics

Some of the prominent players operating in the global vision care market areJohnson & Johnson, Valeant Pharmaceuticals, Novartis, ZEISS and The Cooper Companies.The upcoming TMR report would provide crucial information on their product offerings, market standing, and strategies for progress.

About TMR Research

TMR Research is a premier provider of customized market research and consulting services to business entities keen on succeeding in todays supercharged economic climate. Armed with an experienced, dedicated, and dynamic team of analysts, we are redefining the way our clients conduct business by providing them with authoritative and trusted research studies in tune with the latest methodologies and market trends.

Read more from the original source:
Vision Care Market Poised to Expand at a Robust Pace Over 2028 - Statsflash

Read More...

Neglected tropical diseases leave victims liable to families, says expert – ANI News

November 22nd, 2019 5:54 pm

ANI | Updated: Nov 22, 2019 06:58 IST

Abu Dhabi [UAE], Nov 21 (ANI): Neglected tropical diseases (NTDs), such as intestinal worms in children, river blindness and glaucoma, cause physical disability among the victims and make them liable to their families and societies for the rest of their lives especially in poor countries across the globe, an expert told WAM news agency."Neglected Tropical Diseases, NTDs, affect 1.5 billion people across the globe, causing massive disability. These disabled people cannot work and fully contribute to their communities," said Ellen Agler, CEO of END Fund, a non-governmental organisation working to eliminate NTDs.Diseases like intestinal worms in children hold them back from their school and cause anaemia and growth disorders; river blindness (also known as onchocerciasis) and blinding glaucoma cause blindness at an early age, which affects their ability to study and work, Agler explained in an interview on the sidelines of the Reaching the Last Mile Forum (RLMF) in Abu Dhabi on Tuesday.Therefore, these diseases make a ripple effect on education and economy of a society, she stressed.Presently, there is a funding gap of an estimated USD 300 million a year. "This is a small amount, compared to other global health needs. One of the important things about NTDs is, they can be treated for US$0.50 per person per year," she noted.Agler, from her experience of working in more than 25 countries, recalled that community health workers and teachers play a major role in treating NTDs."In many [poor] countries there are more schools than health clinics, and they are a good platform to capture children who need deworming medicine. Therefore, teachers play an incredible role in treating these diseases," she was quoted saying.Meanwhile, Agler also appreciated Crown Prince of Abu Dhabi, Sheikh Mohamed bin Zayed Al Nahyan, for taking steps in eradicating NTDs."Sheikh Mohamed bin Zayed launched the Reaching the Last Mile Fund, RLMF, two years ago in 2017," the expert said.Administered by the END Fund, RLMF is a 10-year, USD 100 million initiative launched by the Abu Dhabi Crown Prince, supported by the Bill and Melinda Gates Foundation and the UK's Department for International Development, DFID.The Forum aims to pave the way for global elimination of river blindness and Lymphatic filariasis.Caused by parasitic work, the disease leads to severe itching, skin disfigurement, and blindness among more than 197 million people in 31 countries.Studies also estimate that river blindness elimination in Africa could generate up to US$6 billion in economic benefits across the continent.More than 856 million people in 53 countries are in need of treatment for lymphatic filariasis, which is caused by the transmission of filarial parasites through mosquitoes.Lymphatic filariasis damages the lymphatic system, which causes abnormal growth of body parts called elephantiasis and can lead to disability, social stigma, and isolation.In 2018, Reaching the Last Mile Fund delivered over 13.5 million treatments for river blindness and lymphatic filariasis, and trained 76,000 health care workers to help expand treatment and outreach.The Fund is currently targeting river blindness elimination in seven countries: Mali, Senegal, Niger, Chad, Sudan, and Ethiopia in Africa, as well as in Yemen in the Middle East. (ANI)

Read more:
Neglected tropical diseases leave victims liable to families, says expert - ANI News

Read More...

SOLIRIS (eculizumab) Receives Approval in Japan for the Prevention of Relapse in Patients with Neuromyelitis Optica Spectrum Disorder (NMOSD) -…

November 22nd, 2019 5:54 pm

BOSTON--(BUSINESS WIRE)--Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that Japans Ministry of Health, Labour and Welfare (MHLW) has approved the extension of the current marketing authorization of SOLIRIS (eculizumab) to include the prevention of relapse in patients with anti-aquaporin-4 (AQP4) antibody-positive neuromyelitis optica spectrum disorder (NMOSD), including neuromyelitis optica.

We are pleased that the Japanese health authorities have approved SOLIRIS as a new treatment for patients suffering from this complex and unpredictable disease, said John Orloff, M.D., Executive Vice President and Head of Research and Development at Alexion. Nearly all patients treated with SOLIRIS were relapse free at 48 weeks in the Phase 3 PREVENT study, providing new hope for Japanese patients with NMOSD and their clinicians.

NMOSD is a rare, devastating, complement-mediated disorder of the central nervous system characterized by relapses, also referred to as attacks. Each attack can result in stepwise accumulation of disability, including blindness and paralysis and sometimes premature death. NMOSD disproportionately strikes young women in the prime of their lives, with the average age of first onset at just 39 years. Previously known as Devics Disease, NMOSD is often confused with other neurological illnesses such as multiple sclerosis (MS), which can lead to delays in diagnosis and treatment with medicines that can worsen disease progression.

The understanding of NMOSD has rapidly evolved in recent years since complement activation by AQP4 antibodies was identified as an underlying cause of the disease, said Kazuo Fujihara, Professor, Fukushima Medical University, Director of the Multiple Sclerosis & Neuromyelitis Optica Center at Southern Tohoku Research Institute and a principal investigator in the PREVENT trial of SOLIRIS in anti-AQP4 antibody-positive NMOSD. With the first approved medicine for NMOSD in Japan, SOLIRIS will provide highly effective treatment to prevent future relapses in these patients.

The approval of SOLIRIS was based on comprehensive results from the Phase 3 randomized, double-blind placebo controlled PREVENT trial, which were published in The New England Journal of Medicine and a long-term extension study (ECU-NMO-302), which is still underway. In the PREVENT study, patients with NMOSD who were anti-AQP4 antibody-positive were treated with SOLIRIS (n=96) or placebo (n=47). The study met its primary endpoint of prolonging the time to first adjudicated relapse and reducing the risk of relapse. At 48 weeks, 98 percent of patients treated with SOLIRIS were relapse free compared to 63 percent of patients receiving placebo. Of the approximately one quarter of patients treated solely with SOLIRIS monotherapy, without receiving other immunosuppressive therapies, 100 percent were relapse free at 48 weeks compared to 61 percent in the placebo group. Sustained effects of SOLIRIS were observed through 144 weeks of treatment.

The safety profile of SOLIRIS was consistent with that seen for SOLIRIS in other clinical studies and real-world use in its three approved indications. The most common adverse events observed in the PREVENT study were upper respiratory tract infection (29 percent of patients in the SOLIRIS group vs. 13 percent in the placebo group), headache (23 vs. 23 percent), nasopharyngitis (21 vs. 19 percent) and nausea (17 vs. 26 percent). The serious adverse events that were reported for more than one patient in either group were pneumonia (three patients in the SOLIRIS group vs. one patient in the placebo group) and cellulitis, sepsis and urinary tract infection (two patients for each event in the SOLIRIS group vs. no patient in the placebo group). One patient receiving SOLIRIS and concomitant supportive IST died from a pulmonary empyema. The patient had an extensive history of pulmonary disease and was an active smoker. No cases of meningococcal infection were observed in the study.

SOLIRIS was approved for the treatment of NMOSD in adult patients who are anti-AQP4 antibody-positive by the U.S. Food and Drug Administration (FDA) in June 2019 and by the European Commission (EC) in August 2019. SOLIRIS received Orphan Drug Designation (ODD) for the treatment of NMOSD in the U.S., EU and Japan.

About NMOSDNMOSD is a rare and severe, autoimmune, inflammatory disorder that attacks the central nervous system (CNS), in which complement activation due to anti-aquaporin-4 (AQP4) antibodies plays a significant role in the disease process. Patients with NMOSD experience unpredictable attacks, also referred to as relapses, which can cause irreversible damage to the optic nerve and spinal cord and can lead to long-term disability. The most common symptoms of NMOSD are optic neuritis and transverse myelitis. Optic neuritis can cause visual problems including blindness; transverse myelitis can cause mobility problems including paralysis. The disease primarily affects women, often in the prime of their lives, with an average age of onset of 39 years. The prevalence of NMOSD may be more common and more severe in non-Caucasian populations worldwide.

Approximately three quarters (73%) of all patients with NMOSD have AQP4 auto-antibodies. In patients with anti-AQP4 antibody-positive NMOSD, the bodys own immune system can turn against itself to produce auto-antibodies against AQP4, a protein on certain cells in the optic nerve, brain and spinal cord that are critical for the survival of nerve cells. The binding of these anti-AQP4 auto-antibodies activates the complement cascade, another part of the immune system. Complement activation by anti-AQP4 auto-antibodies can cause destruction of vital cells in the CNS, leading to demyelination and to the death of neurons, predominantly in the spinal cord and optic nerve.

About SOLIRISSOLIRIS (eculizumab) is a first-in-class complement inhibitor that works by inhibiting the C5 protein in the terminal part of the complement cascade, a part of the immune system. The terminal complement cascade, when activated in an uncontrolled manner, plays a role in severe rare and ultra-rare disorders. SOLIRIS, an intravenously administered therapy, is approved in the U.S., EU, Japan and other countries as a treatment for adult patients with PNH and for adults and children with aHUS. SOLIRIS is not indicated for the treatment of patients with Shiga-toxin E. coli-related hemolytic uremic syndrome (STEC-HUS). In the U.S., SOLIRIS is also approved for the treatment of generalized MG (gMG) in adult patients who are anti-AChR antibody-positive and for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-AQP4 antibody-positive. In the EU, SOLIRIS is approved as the first and only treatment of refractory gMG in adults who are anti-AChR antibody-positive and for the treatment of NMOSD in adult patients who are anti-aquaporin-4 (AQP4) antibody-positive with a relapsing course of the disease. In Japan SOLIRIS is approved for the treatment of patients with gMG who are anti-AChR antibody-positive and whose symptoms are difficult to control with high-dose intravenous immunoglobulin (IVIG) therapy or plasmapheresis (PLEX).

Important Safety Information

INDICATIONS & IMPORTANT SAFETY INFORMATION FOR SOLIRIS (eculizumab)

INDICATIONS

What is SOLIRIS?SOLIRIS is a prescription medicine called a monoclonal antibody. SOLIRIS is used to treat patients with a disease called Paroxysmal Nocturnal Hemoglobinuria (PNH). SOLIRIS is used to treat adults and children with a disease called atypical Hemolytic Uremic Syndrome (aHUS). SOLIRIS is not for use in treating people with Shiga toxin E. coli related hemolytic uremic syndrome (STEC-HUS). SOLIRIS is used to treat adults with a disease called generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive. SOLIRIS is used to treat adults with a disease called neuromyelitis optica spectrum disorder (NMOSD) who are anti-aquaporin-4 (AQP4) antibody positive. It is not known if SOLIRIS is safe and effective in children with PNH, gMG, or NMOSD.

IMPORTANT SAFETY INFORMATION

SOLIRIS is a medicine that affects the immune system. SOLIRIS can lower the ability of the immune system to fight infections. SOLIRIS increases the chance of getting serious and life-threatening meningococcal infections. Meningococcal infections may quickly become life-threatening and cause death if not recognized and treated early.

Meningococcal vaccines must be received at least two weeks before the first dose of SOLIRIS if one has not already had this vaccine. If ones doctor decided that urgent treatment with SOLIRIS is needed, meningococcal vaccination should be administered as soon as possible. If one has not been vaccinated and SOLIRIS therapy must be initiated immediately, two weeks of antibiotics should also be administered with the vaccinations. If one had a meningococcal vaccine in the past, additional vaccination might be needed before starting SOLIRIS. Patients should ask their doctor if an additional meningococcal vaccination is needed. Meningococcal vaccines reduce the risk of meningococcal infection but do not prevent all meningococcal infections. Call ones doctor or get emergency medical care right away if any of these signs and symptoms of a meningococcal infection occur: headache with nausea or vomiting, headache and fever, headache with a stiff neck or stiff back, fever, fever and a rash, confusion, muscle aches with flu-like symptoms, and eyes sensitive to light. Ones doctor will provide a Patient Safety Card about the risk of meningococcal infection. Carry the card at all times during treatment and for 3 months after the last SOLIRIS dose.

SOLIRIS is only available through a program called the SOLIRIS REMS.

SOLIRIS may also increase the risk of other types of serious infections. If ones child is treated with SOLIRIS, make sure that the child receives vaccinations against Streptococcus pneumoniae and Haemophilus influenzae type b (Hib). Certain people may be at risk of serious infections with gonorrhea. Talk to the doctor about whether one is at risk for gonorrhea infection, about gonorrhea prevention, and regular testing. Certain fungal infections (Aspergillus) may also happen if one takes SOLIRIS and has a weak immune system or a low white blood cell count.

Do not receive SOLIRIS if one has a meningococcal infection, or has not been vaccinated against meningitis infection unless ones doctor decides that urgent treatment with SOLIRIS is needed.

Before one receives SOLIRIS, tell the doctor about all of the medical conditions, including if one: has an infection or fever, is pregnant or plans to become pregnant, and is breastfeeding or plans to breastfeed. It is not known if SOLIRIS will harm an unborn baby or if SOLIRIS passes into the breast milk.

Tell the doctor about all the medicines one takes, including prescription and over-the-counter medicines, vitamins, and herbal supplements. SOLIRIS and other medicines can affect each other, causing side effects. It is important that one: has all recommended vaccinations before starting SOLIRIS, receives 2 weeks of antibiotics if one immediately starts SOLIRIS, and stays up-to-date with all recommended vaccinations during treatment with SOLIRIS. Know the medications one takes and the vaccines one receives. Keep a list of them to show the doctor and pharmacist when one gets a new medicine.

If one has PNH, the doctor will need to monitor closely for at least 8 weeks after stopping SOLIRIS. Stopping treatment with SOLIRIS may cause breakdown of the red blood cells due to PNH. Symptoms or problems that can happen due to red blood cell breakdown include: drop in the number of the red blood cell count, drop in the platelet counts, confusion, kidney problems, blood clots, difficulty breathing, and chest pain. If one has aHUS, the doctor will need to monitor closely during and for at least 12 weeks after stopping treatment for signs of worsening aHUS symptoms or problems related to abnormal clotting (thrombotic microangiopathy). Symptoms or problems that can happen with abnormal clotting may include: stroke, confusion, seizure, chest pain (angina), difficulty breathing, kidney problems, swellings in arms or legs, and a drop in the platelet count. SOLIRIS can cause serious side effects including serious allergic reactions. Serious allergic reactions can happen during ones SOLIRIS infusion. Tell the doctor or nurse right away if one gets any of these symptoms during the SOLIRIS infusion: chest pain, trouble breathing or shortness of breath, swelling of the face, tongue, or throat, and feeling faint or pass out. If one has an allergic reaction to SOLIRIS, the doctor may need to infuse SOLIRIS more slowly, or stop SOLIRIS.

The most common side effects in people with PNH treated with SOLIRIS include: headache, pain or swelling of the nose or throat (nasopharyngitis), back pain, and nausea. The most common side effects in people with aHUS treated with SOLIRIS include: headache, diarrhea, high blood pressure (hypertension), common cold (upper respiratory infection), stomach-area (abdominal) pain, vomiting, pain or swelling of the nose or throat (nasopharyngitis), low red blood cell count (anemia), cough, swelling of legs or feet (peripheral edema), nausea, urinary tract infections, and fever. The most common side effects in people with gMG treated with SOLIRIS include: muscle and joint (musculoskeletal) pain. The most common side effects in people with NMOSD treated with SOLIRIS include: common cold (upper respiratory infection); pain or swelling of the nose or throat (nasopharyngitis); diarrhea; back pain; dizziness; flu like symptoms (influenza) including fever, headache, tiredness, cough, sore throat, and body aches; joint pain (arthralgia); throat irritation (pharyngitis), and bruising (contusion).

Please see the accompanying full Prescribing Information and Medication Guide for SOLIRIS, including BOXED WARNING regarding serious and life-threatening meningococcal infections.

About AlexionAlexion is a global biopharmaceutical company focused on serving patients and families affected by rare diseases through the discovery, development and commercialization of life-changing therapies. As the global leader in complement biology and inhibition for more than 20 years, Alexion has developed and commercializes two approved complement inhibitors to treat patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS), as well as the first and only approved complement inhibitor to treat anti-acetylcholine receptor (AChR) antibody-positive generalized myasthenia gravis (gMG) and neuromyelitis optica spectrum disorder (NMOSD). Alexion also has two highly innovative enzyme replacement therapies for patients with life-threatening and ultra-rare metabolic disorders, hypophosphatasia (HPP) and lysosomal acid lipase deficiency (LAL-D). In addition, the company is developing several mid-to-late-stage therapies, including a second complement inhibitor, a copper-binding agent for Wilson disease and an anti-neonatal Fc receptor (FcRn) antibody for rare Immunoglobulin G (IgG)-mediated diseases as well as several early-stage therapies, including one for light chain (AL) amyloidosis and a second anti-FcRn therapy. Alexion focuses its research efforts on novel molecules and targets in the complement cascade and its development efforts on the core therapeutic areas of hematology, nephrology, neurology, metabolic disorders and cardiology. Headquartered in Boston, Massachusetts, Alexion has offices around the globe and serves patients in more than 50 countries. This press release and further information about Alexion can be found at: http://www.alexion.com.

[ALXN-G]

Forward-Looking StatementThis press release contains forward-looking statements that involve risks and uncertainties relating to future events and the future performance of Alexion, including statements related to: the potential benefits of SOLIRIS as a treatment and prevention of relapse in adult patients with anti-aquaporin-4 (AQP4) antibody-positive neuromyelitis optica spectrum disorder (NMOSD) and the potential impact of SOLIRIS on patients suffering from NMOSD; and that Soliris can help prevent future relapses. Forward-looking statements are subject to factors that may cause Alexion's results and plans to differ materially from those expected by these forward looking statements, including for example: the anticipated benefits of SOLIRIS for NMOSD patients may not be realized (and the results of the clinical trials may not be indicative of the results once approved for use in the European Union); results of clinical trials may not be sufficient to satisfy any other regulatory authority in order to approve SOLIRIS as a treatment for NMOSD (or they may request additional trials or additional information); results in clinical trials may not be indicative of results from later stage or larger clinical trials (or in broader patient populations); the possibility that results of clinical trials are not predictive of safety and efficacy and potency of our products (or we fail to adequately operate or manage our clinical trials) which could cause us to discontinue sales of the product (or halt trials, delay or prevent us from making regulatory approval filings or result in denial of approval of our product candidates); unexpected delays in clinical trials; unexpected concerns regarding products and product candidates that may arise from additional data or analysis obtained during clinical trials or obtained once used by patients following product approval; future product improvements may not be realized due to expense or feasibility or other factors; delays (expected or unexpected) in the time it takes regulatory agencies to review and make determinations on applications for the marketing approval of our products; inability to timely submit (or failure to submit) future applications for regulatory approval for our products and product candidates; inability to timely initiate (or failure to initiate) and complete future clinical trials due to safety issues, IRB decisions, CMC-related issues, expense or unfavorable results from earlier trials (among other reasons); our dependence on sales from Soliris, our principle product; future competition from biosimilars and novel products; decisions of regulatory authorities regarding the adequacy of our research, marketing approval or material limitations on the marketing of our products; delays or the inability to launch product candidates due to regulatory restrictions, anticipated expense or other matters; interruptions or failures in the manufacture and supply of our products and our product candidates; failure to satisfactorily address matters raised by the European Commission and other regulatory agencies regarding products and product candidates; uncertainty of long-term success in developing, licensing or acquiring other product candidates or additional indications for existing products; inability to complete acquisitions or grow the product pipeline through acquisitions (including due to failure to obtain antitrust approvals); the possibility that current rates of adoption of our products are not sustained; the adequacy of our pharmacovigilance and drug safety reporting processes; failure to protect and enforce our data, intellectual property and proprietary rights and the risks and uncertainties relating to intellectual property claims, lawsuits and challenges against us (including intellectual property lawsuits relating to Ultomiris brought by third parties and inter partes reviews of existing patents); the risk that third party payors (including governmental agencies) will not reimburse or continue to reimburse for the use of our products at acceptable rates or at all; failure to realize the benefits and potential of investments, collaborations, licenses and acquisitions; the possibility that expected tax benefits will not be realized; potential declines in sovereign credit ratings or sovereign defaults in countries where we sell our products; delay of collection or reduction in reimbursement due to adverse economic conditions or changes in government and private insurer regulations and approaches to reimbursement; uncertainties surrounding legal proceedings, company investigations and government investigations, including investigations of Alexion by the U.S. Securities and Exchange Commission (SEC) and U.S. Department of Justice; the risk that estimates regarding the number of patients with PNH, aHUS, gMG, NMOSD, HPP and LAL-D and other indications we are pursuing are inaccurate; the risks of changing foreign exchange rates; risks relating to the potential effects of the Company's restructuring; risks related to the acquisition of Syntimmune and other companies and co-development efforts; and a variety of other risks set forth from time to time in Alexion's filings with the SEC, including but not limited to the risks discussed in Alexion's Quarterly Report on Form 10-Q for the quarter ended September 30, 2019 and in our other filings with the SEC. Alexion disclaims any obligation to update any of these forward-looking statements to reflect events or circumstances after the date hereof, except when a duty arises under law.

Read the original:
SOLIRIS (eculizumab) Receives Approval in Japan for the Prevention of Relapse in Patients with Neuromyelitis Optica Spectrum Disorder (NMOSD) -...

Read More...

Autologous Stem Cell and Non Stem Cell Based Therapies Market Shares, Strategies, and Forecasts Analysis – Downey Magazine

November 22nd, 2019 5:53 pm

In autologous stem cell and non-stem cell based therapies, an individuals cell is cultured and then re-introduced to the donors body. Used for the treatment of various bone marrow diseases, autologous stem cell and non-stem cell based therapies allows patients to have normal bone marrow, which gets destroyed in chemotherapy. The various diseases that can be treated with the help of autologous stem cell and non-stem cell based therapies include: multiple myeloma, aplastic anemia, non-Hodgkins lymphoma, Parkinsons disease, Hodgkins lymphoma, thalassemia, and diabetes. Thus, the demand for this therapy is projected to rise over the coming years.

The report is a thorough analysis of theAutologous Stem Cell and Non-Stem Cell Based Therapies Market. Comprising an in-depth analysis of the various factors boosting and inhibiting the growth of the market, this report is a key to making profitable decisions by investing in the correct segment and sub-segment, which is anticipated to make the most progress in the future.

Request a PDF Brochure of Autologous Stem Cell and Non-Stem Cell Based Therapies Market Report https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=4001

Autologous Stem Cell and Non-Stem Cell Based Therapies Market: Trends and Opportunities

One of the key drivers for this market is the rise in the prevalence of cancer and diabetes among people across all age groups. Moreover, the growing geriatric population is another factor, which is likely to create a heightened demand for autologous stem cell and non-stem cell based therapies. Favorable reimbursement policies across several nations are also aiding the growth of this market.

Players in the market are striving to achieve therapies that are not only safe and effective but also affordable and easy to use. Players are also investing in extensive research and development so as to speed up the treatment process of autologous stem cell and non-stem cell based therapies. While currently this treatment is quite expensive, government bodies are expected to take up initiatives and make the therapy affordable in the years to come. This is expected to drive the market in the future.

On the other hand, challenges faced by the global autologous stem cell and non-stem cell based therapies market include risks and complications associated with the therapy, such as diarrhea, hair loss, nausea, severe infections, vomiting, heart complications, and infertility.

Autologous Stem Cell and Non-Stem Cell Based Therapies Market: Geographical Analysis

By geography, North America, trailed by Europe is leading in the autologous stem cell and non-stem cell based therapies market, on account of the minimization of risks associated with the therapy. Also, these therapies are highly in demand owing to their ability to treat a large number of infectious diseases. The fact that autologous stem cell and non-stem cell based therapies do not require an outside donor, makes it more convenient and less infectious. All these factors are boosting the growth of the market in North America.

Asia Pacific is projected to show the most promising growth in the years to come with high demand from China, Vietnam, Malaysia, and India. The demand is expected to be high as autologous stem cell and non-stem cell based therapies help in the effective treatment of cardiovascular diseases. Sophisticated healthcare infrastructure and favorable tax and reimbursement policies are also expected to aid the growth of the Asia Pacific autologous stem cell and non-stem cell based therapies market.

Request for a Discount on Autologous Stem Cell and Non-Stem Cell Based Therapies Market Report https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=4001

Autologous Stem Cell and Non-Stem Cell Based Therapies Market: Companies Mentioned

Some of the leading players operating in the autologous stem cell and non-stem cell based therapies market are Fibrocell Science, Inc., Aastrom Biosciences, Dendreon Corporation, NeoStem, Inc., BrainStorm Cell Therapeutics, Regeneus Ltd., and Genzyme Corporation.

Read more here:
Autologous Stem Cell and Non Stem Cell Based Therapies Market Shares, Strategies, and Forecasts Analysis - Downey Magazine

Read More...

Missing Link To Longevity Discovered In The Plant Kingdom – Texas A&M University

November 22nd, 2019 5:52 pm

lead researcher Dorothy Shippen, Ph.D., (left), graduate student Jiarui Song, first author (center) and postdoctoral fellow Claudia Castillo-Gonzlez, second author (right).

Texas A&M AgriLife

A breakthrough discovery by Texas A&M University and Arizona State University professors could provide a key component in understanding the human aging process and even aid in the battle against cancer.

Dorothy Shippen, Ph.D., is a University Distinguished Professor and Regents Fellow in Texas A&MsDepartment of Biochemistry and Biophysicsand withTexas A&M AgriLife Research, College Station.

Shippen co-led a study with Julian Chen, Ph.D., professor of biochemistry, Arizona State Universitys School of Molecular Sciences. First author, Jiarui Song, is a graduate student with Shippen.

Their study, The conserved structure of plant telomerase RNA provides the missing link for an evolutionary pathway from ciliates to humans, is being published in the Proceedings of the National Academy of Sciences.

Our discovery of this key component of the telomerase enzyme in the plant kingdom provides an evolutionary bridge, and a novel path forward, for understanding how humans keep their DNA safe and enable cells to divide indefinitely, Shippen said.

Moreover, since plants often evolve interesting solutions to fundamental biological problems, some of the lessons we learn from plant telomerases may provide new ways for addressing stem cell disease and cancer.

We found a core component of the telomerase enzyme that had been missing all these years, Shippen said. And by finding this component in plants, we not only learn new lessons about how telomerase evolved, but we also open the door to learn new things about the human enzyme.

Back in 2001, Shippen published a paper outlining the discovery of the catalytic subunit of the telomerase enzyme from plants. The catalytic component is one of two absolutely critical parts of the enzyme, and it is now very well understood.

However, the second component, the RNA subunit, that provides the enzyme with information about what to do with chromosome ends, was missing.

Our new discovery is the RNA subunit of telomerase from the plant kingdom. In the plant telomerase RNA, we can now see the signatures for the human telomerase and telomerase from simple organisms like bakers yeast and the microbes in pond scum.

The missing piece always was this subunit. Now that we have found the correct one, its opened up a lot of interesting insights.

Plants have different, innovative solutions to so many biological challenges, and insight into these may provide important clues on how human telomerase is regulated, she said.

We can study the telomerase enzyme more deeply and see so much more now, and it can help us understand how the human enzyme is going to work. It really is this missing middle ground.

In the 1930s, Barbara McClintockwas studying the behavior of chromosomes in maize and was one of the first scientists to appreciate the importance of telomeres.The Shippen Labin the 1990s followed up on the pioneering work of McClintock in model plant systems and discovered the telomerase enzyme, which is required for maintaining these structures on the ends of chromosomes.

Shippens longtime studies on telomerase, which play an essential role in chromosome stability and cell proliferation capacity, has led her to be considered the worlds expert in plant telomere research.

The telomere is like a biological clock. There is a certain amount of telomeric DNA at the end of chromosomes. As cells divide, they lose part of this DNA.

She has likened telomeres to the plastic tip on the end of a shoelace they form a protective seal on the ends of chromosomes in plants and animals. Like the plastic tip that wears out, allowing the shoelace to fray and become hard to use, so does the telomere break down in most cells in the human body over time.

The telomerase enzyme is capable of replenishing the lost DNA at chromosome ends and it is available in cells that are immortal, Shippen said. Its active in the stem cells, but not active in other places of the body normally.

Theres a whole connection between immortality and telomerase that needs to be studied.

Why is telomerase only active in stem cells, turned off in other cells and why does it get reactivated in cancer cells? Shippen said. Weve learned a lot about the human telomerase from pond scum, but plants can provide still more clues because their growth and development is so plastic. If you cut a flower from a plant growing in the garden, it will grow another flower. But if you cut off the tip of your finger, you wont be growing a new one.

Its a big mystery.

But Shippen said the plant telomerase is still very similar to the human telomerase.

It is remarkable that even in plants, telomerase is active only in cells that need to divide many times.

She expects that what is learned in the plant system will ultimately be translatable and have significant impact in human medicine.

See the original post:
Missing Link To Longevity Discovered In The Plant Kingdom - Texas A&M University

Read More...

The New Face of Longevity: Dwayne Clark’s Solution to America’s Silver Tsunami Crisis and How Living on Stolen Potatoes Made It All Possible -…

November 22nd, 2019 5:52 pm

November21, 201910 min read

Opinions expressed by Entrepreneur contributors are their own.

If you ask Dwayne Clark, founder and CEO of the senior care company Aegis Living, what he is most thankful for in life, he will unabashedly tell you growing up poor.

For Clark, a childhood spent in poverty instilled a compassion-first mentality and a burning desire to help others lead lives of dignity.

Today, Clark is seen as a change-maker in his industry. Aegis opened its 32nd location this year and has eight more facilities in development. The company is on track to have operating revenues of over $300 million in 2020, with real estate holdings approaching $3 billion.

Clark is the youngest of four children raised by a single mother in Walla Walla, Washington. When he was 16, his mother told him they were completely broke and had no money for food.

The youngest of four children, Clark was raised by a single mother who struggled to feed her family.

Image credit: Dwayne Clark

To feed her family, she made potato soup from a bag of potatoes shed stolen from the restaurant where she worked as a line cook. She vowed to replace the potatoes when she had money again. While Clark felt powerless to help his mother, he remembers being in awe of her strength and resilience.

My background truly is a gift to me, he says. It helps me relate to the dishwasher and has given me an affinity for struggling immigrants, for the poor kid, whoever needs help. If I hadnt grown up knowing what being hungry is really like, I would not have created the business I run today.

By the time he was 26 years old, Clark had worked his way up from a correctional officer to shift commander at Washington States Department of Corrections. He was good at it, but he hated the job. He wanted to go back to college (hed dropped out in his junior year) and then to law school, but his sister interrupted these plans with a call out of the blue. She insisted he read a new study about aging in America.

This was before we had the internet and I could just pull it up on a computer; so I went to the library to look up the study, says Clark. It was around 400 pages. I didnt particularly want to read it, but it seemed important to her. So I read the whole thing and realized there was a silver tsunami coming fast.

He learned that life expectancy was on the rise and the elderly population was expected to double. His takeaway: eldercare was going to be a booming industry. Clarks sister was on the advisory board of one of Leisure Cares communities, so he asked her to help get him an interview.

I didn't want this to be a courtesy 10- to 15-minute interview. So when they asked if I could come in for an interview that next week, I said I could come in 30 days, says Dwayne. I wanted to do my research on the company, their competitors, and the industry. I wanted to be the best interview theyd had in 10 years.

Thirty days later, Dwayne went in for the interview, and, as expected, they asked a few cursory questions, spent no more than 10 minutes with him, and thanked him for coming in. Before they could shoo him out the door, Dwayne reached into his backpack and pulled out a three-ring binder and dropped it on the desk in front of him.

Id like to talk to you about where I think the aging industry is going and how I think I could contribute, he told them. Clark says they spent the next 90 minutes going over his manual, and they made him a job offer within the week.

Leisure Care hired Clark as the marketing director in Colorado. Forty-five days later he was put in a manager training program, and two years later he was named VP of Operations.

At age 33, Clark was recruited by Sunrise Senior Living, which would the biggest senior housing company in the world. In less than five years he helped grow Sunrise from an $18 million company to a company with a $3 billion market cap.

Despite his seemingly overnight success in the eldercare industry, Clark wasnt satisfied working for a public company. He decided to quit and make his own way.

It wasnt in my personality, and I didnt like what Wall Street did to the culture of the companies, says Dwayne. I thought I needed to just do it on my own.

You need a significant amount of money to do well in the senior care industry, and I dont mean $10 million; I mean tens of millions of dollars, he says. Today you would need $150 million to start a company like Aegis.

Dwayne spent much of 1996 looking for partners and capital sources and eventually found the right person: a developer in California named Bill Gallaher, whom Clark had built a relationship with during his time at Sunrise.

Together they founded Aegis, were able to raise $10 million, and built their first property in Pleasant Hill, California, in 1998. But it wasnt all smooth sailing.

I underestimated just how capital intensive the process was, says Clark. We burned through that first $10 million in six to nine months.

After two more rounds of capital financing, which yielded another $12.5 million, Gallaher called and told him they were out of money. By this point, Clark had exhausted all his resources except his sons college fund.

My son had just committed to UCLA, his dream school, says Clark. I needed the college money to cover payroll or Aegis could not stay afloat. I had to go to my son and have a tough conversation. I said, You know, that in-state tuition at the University of Washington looks really good.

Thankfully, his son understood and never felt bitter about the decision to abandon UCLA. Clark credits the college fund for saving the company.

In 2007, Clark says he bought out Gallaher due to a difference in philosophies. He took full control of Aegis and set out to grow it into the premier assisted living community on the West Coast.

As the company expanded, Clark became an expert on how to care for people with Alzheimers and dementia. He believed hed learned everything there was to know about how to manage this type of care facility until the day he received a massive blow that challenged him as a CEO and son: his mother was diagnosed with Alzheimers.

Image credit: Dwayne Clark

Imagine the feeling of being the guy leading the industry in this type of care but I couldnt help my own mother, admits Dwayne.

She moved into one of his memory-care communities, and Clark began to have a major shift in perspective. It was a game changer, he says.

His mother loved music; so Clark read studies on the positive effects of music on patients with dementia and Alzheimers and expanded the music programs in his Alzheimers wing.

She also loved doing her hair and make-up, which became harder as her illness worsened. As a result, Clark brought traveling salons to his senior health communities to give all the residents makeovers. This started a long list of improvements throughout his facilities that werent always good for his companys bottom line but he believes improved the lives of the residents. Clark says he created hundreds of longevity aids, including aromatherapy to improve mental clarity, spring-loaded chairs to allow seniors to stand without assistance, and shorter hallways to facilitate walking.

Clark also took action to create a culture where employees feel genuinely invested in and cared about.

I want to be an employee-first company because I truly believe culture is everything, says Clark. We are a service-oriented company that aims to do our part in treating the Alzheimers epidemic by serving the high-risk communities of senior health.

Clark created a program called E.P.I.C. (Empowering People Inspiring Consciousness) to transform Aegis Livings annual meeting from a traditional year-end review to a three-day celebration of the human spirit. It is a seminar for self-improvement with the primary agenda to ignite personal development among the employees. E.P.I.C. attracts celebrities like Michael J. Fox, Carlos Santana, and Dr. Deepak Chopra to teach and inspire his employees.

Clark says one of his lifelong obsessions has been the pursuit of health understanding it and attaining it. As a young adult, he lost sight of that passion and burned the proverbial candle at both ends. He worked long hours, lived on a junk-food diet, partied late into the night, and slept very little.

Everything came to a head one Labor Day weekend with his wife, when he began to experience the most acute abdominal pain of his life. It was so bad that he ended up in the hospital where he was diagnosed with severe gastritis.

Clark says the experience was a wake-up call. Hed learned so much caring for people well into their 100s, but ironically, hed never consciously applied those lessons to himself.

My health crisis inspired me to seek out longevity, study it, achieve more of it, and share my findings with a broader audience, says Clark. While Id been living and breathing questions about the health and longevity of my Aegis residents, Id separated myself from what Id learned. Overnight, my commitment changed.

Dwayne became a longevity explorer, traveling to over 80 countries to interview hundreds of people on what it means to age well into their 80s, 90s and 100s. His obsession with health and longevity led him on a journey of research into finding every conceivable way to live a more vibrant, healthier, and more fulfilled life.

In his latest book, 30 Summers More, Dwayne takes what he has learned about longevity by caring for more than 60,000 residents and writes a new plan for aging in America. He challenges the status quo for people over age 60, using the wisdom of Aegis residents.

Clark, far right, with former Secretary of State Hilary Clinton, former President Bill Clinton, and Clarks wife, Terese, after a lunch where the couples discussed politics, business, and longevity.

Image credit: Dwayne Clark

Hes also taken an interest in exploring what makes successful people tick, and Clarks recently launched podcast, Walk This Way, discusses the journey of CEOs, athletes, and celebrities and how they made their way to hit mega-success by not following the traditional path.

Clarks own path was no doubt untraditional.

I have never had a woe is me mentality or seen my background as a drawback, says Clark. Entrepreneurs share one thing: theyre trying to run as fast as they can away from poverty. It creates rocket fuel for them to be successful.

Follow Dwayne Clark on Instagram, Facebook, and LinkedIn, or visit his website.

See the original post:
The New Face of Longevity: Dwayne Clark's Solution to America's Silver Tsunami Crisis and How Living on Stolen Potatoes Made It All Possible -...

Read More...

Longevity Project explores the nuanced implications of longer life – PRNewswire

November 22nd, 2019 5:52 pm

WASHINGTON, Nov. 19, 2019 /PRNewswire/ -- As longer life expectancy brings about substantial changes in the make-up of American society, Americans are still grappling with the implications of longer life on how we work, live and learn, according to a poll fielded by the Longevity Project, a new initiative developed in collaboration with the Stanford Center on Longevity (SCL). The mission of the Longevity Project is to generate research and foster public dialogue on the far-reaching impact of increased longevity.

Some key results of the Longevity Project Morning Consult poll include:

By 2034, Americans over the age of 65 will outnumber children under 18 for the first time in history a change more frequently viewed as a negative outcome than a positive one.

And as people over the age of 55 are poised to become the largest segment of the U.S. workforce, nearly a quarter (23%) of Americans think the retirement age should be lowered to make room for younger workers.

"With Americans living longer and healthier, we have a unique opportunity to reimagine healthy, successful century long lives," said Laura Carstensen, Professor of Psychology at Stanford and the founding director of SCL. "But we can't achieve what we can't imagine, and we are pleased to help launch this initiative to foster public understanding and engagement on longevity."

Through research, conferences and events at Stanford and around the country, the Longevity Project will engage with government and business leaders on the policies and methods for supporting longer life. Conferences will include the Century Summit and Longevity Next, the first longevity conference focused on engaging millennials and Generation X about the implications of longer life.

"We are proud to work with a growing coalition of organizations including the Stanford Center on Longevity, the Urban Institute, Morning Consult, the National Academy of Medicine, and a group of forward thinking companies comprised of Principal Financial Group, Wells Fargo, and Instructure to launch this important initiative, said Ken Stern, co-chair of the Longevity Project."

The project's first poll underscores a disconnect between public perceptions of aging and the real influence of longer lifespan. A decade ago, a Pew Research Center poll put the beginning of "old age" at 68. The Longevity Project's respondents pegged the answer at a younger age, 66 -- a surprising change in an era in which many people in their 60s and 70s continue to play a significant role in public life.

Other key findings of the Longevity Project Morning Consult poll include:

View the full research findings and additional project information at http://www.longevity-project.com.

The Longevity Project, in partnership with Morning Consult, will release a larger study of longevity issues in January, and will be convening multiple forums in the coming months to explore the best approaches to promoting an effective and beneficial longer life.

Contact; Kaila Lewis kaila.lewis@palisadesmv.com443-433-6113

SOURCE Longevity Project

https://www.longevity-project.com

Read the original here:
Longevity Project explores the nuanced implications of longer life - PRNewswire

Read More...

2nd Annual Innovation Summit Focuses on Needs of Older Adults and Longevity Economy – PRNewswire

November 22nd, 2019 5:52 pm

WASHINGTON, Nov. 20, 2019 /PRNewswire/ -- The Washington Innovation in Longevity Summit, produced by Mary Furlong & Associates and the Centre for Aging + Brain Health Innovation, kicks off its second annual event on December 9th & 10th at the National Press Club. The successful inaugural event featured government agencies, nonprofits, investors, thought leaders in aging, media, and private companies focused on the needs of older adults and the burgeoning longevity economy.

Keynote speakers for the 2019 Summit include Nancy LeaMond, Executive Vice President, Chief Advocacy and Engagement Officer for AARP; and George Vradenburg, Co-founder and Chairman for UsAgainstAlzheimer's.

Jean Accius, PhD, Senior Vice President, AARP Thought Leadership and International Affairs, AARP International, and Jim Firman, EdD, President and CEO, National Council on Aging (NCOA)will open the Summit to share their unique perspectives on the unmet needs and market opportunities in serving the needs of millions of older people in the US and globally.The two-day summit focuses on the themes of Mobility, Money, Memory, Military and Media.

"Last year's Summit in Washington surpassed our expectations in terms of thought leadership, attendees, and the partnerships that were created," said Mary Furlong, Executive Producer and CEO of Mary Furlong & Associates. "We are excited to bring the Washington Innovation in Longevity Summit to our nation's capital. Our goal is to foster a learning community and network for entrepreneurs, investors, regulators, NGOs and the media, all focused on the growth of the longevity economy and serving the needs of older adults. This conference is the epicenter."

The Washington Innovation in Longevity Summit Day 1 Agenda focuses on the collaborative power of nonprofits, media, and government regulators, working in concert with entrepreneurs and investors. Day 2 is dedicated to global health partnerships in brain health, understanding go to market strategies worldwide, and helping entrepreneurs from other countries navigate the U.S. and Canadian markets.

The full agenda and summit details are here. Summit registration is available here. Key sponsors for the Summit include:

Platinum: AARP, Center for Aging + Brain Health InnovationGold: Ageless Innovation, CareLinx, Sodexo, Thrive Alliance, Posit Science

About Mary Furlong & AssociatesFor 17 years, Mary Furlong & Associates (MFA), headquartered in the San Francisco Bay area, has developed strategies for marketing and business development for companies focused on opportunities with the senior and baby boomer markets and the longevity economy. Dr. Furlong is the executive producer of three conferences annually: What's Next Boomer Business Summit, Silicon Valley Boomer Venture Summit, and Washington Innovation in Longevity Summit. She also co-produces What's Next Canada and is scheduled to add a fourth conference in Paris, France, focused on international aging.

INFORMATION:Ben Adkins 229649@email4pr.com502.619.4267

SOURCE Mary Furlong & Associates

http://www.maryfurlong.com

More:
2nd Annual Innovation Summit Focuses on Needs of Older Adults and Longevity Economy - PRNewswire

Read More...

Page 822«..1020..821822823824..830840..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick